


DALDA TFA

Cat. No.:	HY-P3870B
Molecular Formula:	$C_{30}H_{45}N_9O_5 \cdot xC_2HF_3O_2$
Sequence:	Tyr-[d-Arg]-Phe-Lys-NH ₂
Sequence Shortening:	Y-[d-Arg]-FK-NH ₂
Target:	Opioid Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	DALDA TFA is a potent and highly selective μ -opioid receptor agonist with a K_i of 1.69 nM. DALDA TFA shows antinociceptive and respiratory effects ^[1] .
In Vitro	DALDA carries a net positive charge (3+) at physiological pH and is thus hydrophilic and more polar than morphine ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	DALDA (0-7 nmol/rat; i.t.; once) shows antinociceptive and respiratory effects in rats ^[1] . DALDA (0.1 and 1.0 μ g/side; ICV; once) results in biphasic effects, with an initial suppression, an intermediate marked inhibition, followed by activation for horizontal movement, rearing and stereotypy times in rats ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Shimoyama M, et al. Antinociceptive and respiratory effects of intrathecal H-Tyr-D-Arg-Phe-Lys-NH₂ (DALDA) and [Dmt1] DALDA. *Journal of Pharmacology and Experimental Therapeutics*, 2001, 297(1): 364-371.

[2]. Meyer ME, et al. DALDA (H-Tyr-D-Arg-Phe-Lys-NH₂), a potent mu-opioid peptide agonist, affects various patterns of locomotor activities. *Pharmacol Biochem Behav*. 1995 May;51(1):149-51.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA